Five Big Pharma Products That Saw Action In India; There’s More To Come

Scrip spotlights the action around five key big pharma products in India. We track the gains made by Rybelsus and Keytruda, the wave of Januvia and Ibrance generics and on-market and court action for blockbuster Entresto.

Competition Planes
Key Big Pharma Brands Witness Market Action • Source: Shutterstock

If 2022 saw Novo Nordisk A/S’s Rybelsus (semaglutide) and MSD’s Keytruda (pembrolizumab) make significant traction and Januvia (sitagliptin) generics flood the Indian market, then things are simmering in the new year both on and off the market for products like Novartis AG’s Entresto (sacubitril/valsartan). Pfizer Inc.’s Ibrance (palbociclib) is now facing the full onslaught of cut-price copies.

Scrip tells you how things are poised and what to expect in the new year for these products on the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip